Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at
Wall Street
Emergent Biosolutions (NYSE:EBS) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.